Medite Cancer Diagnostics, Inc. (MDIT)
Makes lab equipment and tests to diagnose cancer from tissue samples.
$0.00+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+0.0%
The outlook
MDIT is trading at its 52-week low with a neutral analyst outlook. The stock sits above both its 50- and 200-day moving averages, suggesting some near-term support, though overall sentiment remains measured at 48/100.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
$8,672
52-wk high
$0.01
52-wk low
$0.00
50-day avg
$0.00
200-day avg
$0.00
Trailing P/E
—